Disc Medicine, Inc. 8K

Disc Medicine reported encouraging initial Phase 2 RESTORE-PV trial data for DISC-3405 in polycythemia vera, demonstrating hematocrit control and major reductions in phlebotomy needs, and outlined next developmental milestones for both DISC-3405 and selcodebart.

Disc Medicine, Inc. announced initial positive results from its RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera, showing that the anti-TMPRSS6 monoclonal antibody increased hepcidin, reduced serum iron, controlled hematocrit, and significantly lowered phlebotomy requirements with improved symptom burden and a generally well-tolerated safety profile; the company also highlighted prior positive Phase 2 RALLY-MF data for selcodebart (DISC-0974) in anemia of myelofibrosis and outlined plans to provide further updates on DISC-3405 trials in PV and sickle cell disease and on pivotal development planning for selcodebart by the end of 2026.

Filing Facts

CIK

1816736

Ticker

IRON

Form

8K

Source Type

fda

Accession

0001193125-26-387351

Alert Tier

6